Summary During the last decades (À)-deprenyl has become the golden standard of MAO-B inhibitors. It possesses dopamine potentiating and antioxidant properties; however, its effects cannot be explained solely by the enzyme inhibitory action. (À)-Deprenyl prevents the toxicity of certain selective neurotoxins and recently it was demonstrated to increase cell-cell adhesion as well. The complexity of its pharmacological effects reflects the action of both the parent compound and the active metabolites. (À)-Deprenyl and related propargylamines (DRPs) show neuroprotective features in a variety of in vitro and in vivo models that is dependent on the propargyl moiety. The main presumptive targets to date include glyceraldehyde-3-phosphate dehydrogenase, poly(ADP-ribose) polymerase, some kinase cascades, as well as pro-and antiapoptotic proteins, beside the inhibition of MAO-B. The antiapoptotic activity of DRPs converges upon the maintenance of mitochondrial integrity, due to the initiation of a complex transcriptional program, the details of which are yet to be elucidated.
Introduction
If we take a look at the last decades of Hungarian drug research (À)-deprenyl reached the largest success from the scientific point of view. It was synthesized in 1962 as a ''psychic energizer'', together with many other monoamine oxidase (MAO) inhibitors. Soon became clear, that these compounds were effective antidepressants, but because of their serious side effects, the ''cheese reaction'', they fell into disrepute and tricyclic compounds became the drugs of choice in the treatment of depression. (À)-Deprenyl fell into the same basket.
Not much later, the outstanding discovery of Johnston in 1968 helped resuscitate (À)-deprenyl (Johnston, 1968) . He described that on the basis of substrate specificity and inhibitor sensitivity MAO has two isoforms. The clorgyline sensitive izoenzyme was named MAO-A, while the insensitive MAO-B. The preferred substrate of MAO-A is serotonin (5-HT), whereas that of the B-isoform is b-phenylethylamine (PEA). Regarding inhibitor specificity, (À)-deprenyl preferentially blocks MAO-B, in contrast to clorgyline, the known selective inhibitor of MAO-A. The non-selective and the A-type selective blockers induce ''cheese reaction'' and are potent antidepressants, whereas the B-type selective inhibitors of MAO neither trigger this serious side effect, nor are in possession of the antidepressive properties. Nevertheless, they potentiate the effect of dopamine (DA) and show antioxidant characteristics. Due to these beneficial actions, (À)-deprenyl has found its therapeutic role in the treatment of Parkinson's disease (PD) .
Regarding the milestones of the history of (À)-deprenyl the following events can be highlighted: The first pharmacological paper came out in 1965 (Knoll et al., 1965) . In 1967, the (À)-isomer was declared to be responsible for the most part for MAO-B inhibition (Magyar et al., 1967) . (À)-Deprenyl was demonstrated to be a selective inhibitor of MAO-B, in contrast to clorgyline (Knoll and Magyar, 1972) . The paper dealing with this issue was published in 1972, and became ''science citation classic'' since then. Based on clinical observations, Birkmayer and his group stated that (À)-deprenyl potentiated the effect of levodopa and improved the quality of life of parkinsonian patients (Birkmayer et al., 1977) . The same group was the first to publish that (À)-deprenyl possesses neuroprotective features and delays disease progression in PD patients (Birkmayer et al., 1985) .
During the last 25 years more than 2000 papers have been published in the literature dealing primarily with (À)-deprenyl, and it has been registered for treating PD in more than 40 countries. (À)-Deprenyl played an essential role in MAO research, not only due to its clinical effects, but also by facilitating the discovery of MAO inhibitors with a propargyl group, similarly to (À)-deprenyl. Present research focuses on the elucidation of the effect of (À)-deprenyl and its congeners in neuroprotection and neuronal rescue.
The synthesis of irreversible inhibitors of MAO
During the early sixties more than 200 compounds have been synthesized in the Chinoin Pharmaceutical Company (Budapest, Hungary) -including (À)-deprenyl -with the aim of developing potent and selective MAO inhibitors (Magyar et al., 1980) . All of these compounds possessed a propargylamine structure, and in view of their large number some structure-activity relationships (SAR) were possible to be established. (À)-Deprenyl was synthesized by the Chinoin chemist Z. Ecseri, who attached the well known propargyl group of pargyline to methylamphetamine. These compounds were so called mechanism based ''suicide inhibitors'', which first bind to the target enzyme, where they are converted to an active compound forming a covalent bond with the active center of the enzyme. Because of the irreversible nature of inhibition, the maintenance of selectivity is troublesome during prolonged administration of these drugs. This difficulty may be overcome by the administration of low doses (Ekstedt et al., 1979) . The inhibitors usually show stereo selectivity; R-isomers, such as R-(À)-deprenyl or the R-(þ)-enantiomer of J-508 proved to be more potent blockers of MAO-B. Valuable pieces of information were obtained from SARs, which could be summarized as follows:
1. Side chain substitution of (À)-deprenyl at a-position with an ethyl, isopropyl or a benzyl group decreased the MAO inhibitory potency of the compounds. 2. Ring substitution (halogenation, methoxy-substitution, saturation) generally diminished inhibitory potency, except in case of p-fluoro-deprenyl, which proved to be an irreversible, potent B-type selective MAO inhibitor, with equal potency and selectivity to (À)-deprenyl. 3. Omitting the methyl group of deprenyl in the a-position of the side chain (TZ-650) did not change the potency and the stereo-selective action of the parent compound. 4. Replacing the phenyl ring by a furan [(À)-U-1424] or an indanyl group [(þ)-J-508] gave birth to valuable selective inhibitors of MAO-B. AGN-1135, also known as rasagiline, is the N-desmethyl derivative of AGN-1133 (same as J-508), which was extensively investigated by Youdim and Finberg (Youdim and Finberg, 1986) , and is now at the end of clinical studies. 5. Ring alterations led to A-type selective MAO inhibitors in many cases.
The chemical structures of some selected, newly synthesized compounds and their relative potency compared to (À)-deprenyl are depicted in Fig. 1 . MAO activity was determined in nuclei free homogenates of rat forebrain, using 14 C-labeled b-PEA and 5-HT as selective substrates. The IC 50 values of the new compounds were compared to that of (À)-deprenyl. (À)-U-1424 and (þ)-J-508 are B-type selective MAO inhibitors. The first compound is slightly less potent; however, the efficacy of the latter exceeded that of (À)-deprenyl by one order of magnitude.
( 2 )-Deprenyl protects against selective neurotoxins Understanding the mode of action of selective neurotoxins allowed deeper insight into the possible mechanisms of neurodegeneration, thus, facilitating the development of effective neuroprotective substances. Monoamine transmitters are inactivated by means of a membrane-bound high-affinity, energy-and sodium ion-dependent uptake process. Toxins, being structural analogues to these transmitters, can enter the cell by the same reuptake mechanism, and once inside, they cause selective injury to the neuron. The most widely studied neurotoxins are shown in Table 1 . Selective neurotoxins of Table 1 decrease the transmitter content of the rat brain, which can be prevented by (À)-deprenyl pretreatment. Most of these studies have been carried out with the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), whereas our laboratory thoroughly investigated the effect of N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4), a selective noradrenergic neurotoxin as well. In our experiments, DSP-4 was injected i.p., and the noradrenaline (NA) content of the rat hippocampus was determined by an HPLC-EC method, 7 days after DSP-4 treatment. (À)-Deprenyl was administered 1 h before DSP-4 injection. Our recent studies demonstrated that various routes (i.p., oral) and doses (0.25-10 mg=kg) of (À)-deprenyl pretreatment exerted protective effects against DSP-4 induced NA depletion (Fig. 2) . Rasagiline, which is a more potent inhibitor of MAO-B than (À)-deprenyl, but lacks uptake inhibitory properties, was not able to prevent DSP-4 induced NA depletion in doses of 1 to 10 mg=kg (for review see: .
Nevertheless, some contradictory data have also accumulated. Clorgylin, despite its inhibitory action on NA reuptake, does not preclude DSP-4 toxicity. In addition, N-2-hexyl-N-methyl-propargylamine (2-HxMP), a potent selective blocker of MAO-B, without uptake inhibitory features, protects against the NA depleting effect of DSP-4 (for review see: . It seems possible that the inhibition of uptake cannot fully explain the protection against DSP-4 toxicity, other, yet unknown, mechanisms might also play a role.
Pharmacokinetics and metabolism of ( 2 )-deprenyl Therapeutic usage of (À)-deprenyl is based on its DA potentiating effects. The parent compound is established to be responsible for the irreversible inhibition of MAO-B enzyme (for review . Beside MAO-B inhibition, other mechanisms of action responsible for the therapeutic effects of (À)-deprenyl have also been suggested, and the contribution of the metabolites to its versatile pharmacological profile seems to be essential (Lange et al., 1994; Jenner and Olanow, 1996; Tatton and Chalmers-Redman, 1996; Magyar et al., 1998) .
(À)-Deprenyl has considerable first-pass metabolism after oral administration both in humans (Heinonen et al., 1989) and rats , and its bioavailability was proved significantly different after various routes of drug administration . In humans, rapid oral absorption and low bioavailability was observed (Heinonen et al., 1989; Mahmood, 1997) . According to whole body autoradiography and PET studies (Fowler et al., 2001) , its maximum brain concentration is reached rapidly, and it is found mainly in brain regions rich in MAO-B enzyme. Reduction of MAO-B activity quickly develops even after a single dose of (À)-deprenyl (Riederer et al., 1978) , and is a long-lasting effect because of the irreversible inhibition and slow recovery of the enzyme. The bioavailability was shown to be increased when (À)-deprenyl is administered repeatedly or when taken after food (Barrett et al., 1996a; Laine et al., 2000) . Recently, dosage forms providing less first-pass metabolism, such as transdermal patches (Barrett et al., 1996b) or orally disintegrating tablets (Lew, 2005) have been developed, providing higher and more prolonged plasma level of unchanged (À)-deprenyl and lower concentrations of the metabolites compared to those, after oral administration. Because of the considerable metabolic instability of (À)-deprenyl, its plasma and brain concentration is exceeded by some of its metabolites when administered orally (Heinonen et al., 1989; Magyar et al., 1995 .
Desalkylation is recognized as the main metabolic conversion of (À)-deprenyl both in humans and rats: methamphetamine (MA), amphetamine (A) and desmethyldeprenyl (DD) are thus formed (Reynolds et al., 1978; Yoshida et al., 1986; Heinonen et al., 1989) . In humans, as well as in rats, MA was proved as the main metabolite of (À)-deprenyl (Reynolds et al., 1978; Heinonen et al., 1989; Shin, 1997; Szök} o o et al., 1999) . In human studies, about 20-60% of a single (À)-deprenyl dose was recovered as MA from the urine within 72 h after treatment (Heinonen et al., 1989; Shin, 1997; Katagi et al., 2002) , with considerable interindividual Fig. 2 . The effect of different doses of (À)-deprenyl and rasagiline pretreatment (mg=kg; po) on noradrenaline depletion in rat hippocampus Deprenyl: from chemical synthesis to neuroprotection differences. Interestingly, in case of the other enantiomer, (þ)-deprenyl, no considerable excess of the formation of MA compared to A was observed. A and MA formed in similar quantities from (þ)-deprenyl both in humans and rats (Lengyel et al., 1997; Szök} o o et al., 1999) . In all human studies, very low amount of DD (less than 1.5% of the dose) was detected in the urine (Heinonen et al., 1989; Shin, 1997; Katagi et al., 2002) .
During desalkylation, the optical centre on the a-carbon did not change, R-(À)-metabolites are formed from R-(À)-deprenyl (Szök} o o and Shin, 1997) . The stereochemistry of the metabolites does have importance, because of the differing pharmacological potency of the enantiomers: R-(À)-MA is a less potent inhibitor of NA and DA uptake than the S-(þ)-enantiomer (Tekes and Magyar, 2000) . The stereospecific formation of the amphetamine metabolites is in line with the pharmacological differences found between deprenyl enantiomers. (þ)-Deprenyl was shown to induce more hyperthermia and possess amphetamine-like psychostimulant effect (Magyar et al., 1967) . The different enantiomer forms of the active metabolites should be responsible for these differences. The metabolic studies aimed at the identification of the enantiomeric form of the chiral metabolites of (À)-deprenyl has interest not only to gain information about the stereochemistry of the metabolizing enzymes, but also has forensic importance, because it allows making distinction between (À)-deprenyl and illicit amphetamine users. Cytochrome P450 enzymes are recognized to convert (À)-deprenyl to desalkylated metabolites, although the identification of the isoenzymes involved is equivocal. Based on experiments using various CYP isoform-selective inhibitors, the contribution of CYP2D6 (Grace et al., 1994; Bach et al., 2000) , CYP1A2, CYP3A4 (Taavitsainen et al., 2000) , and CYP2E1 (Valoti et al., 2000) isoforms to the formation of deprenyl metabolites by desmethylation and despropynylation, has been Fig. 3 . Metabolic pathways of (À)-deprenyl suggested. In another type of in vitro metabolic study, beside CYP1A2, the involvement of CYP2B6, CYP2C8 and CYP2C19 isoforms in the desalkylation of (À)-deprenyl has been demonstrated (Salonen et al., 2003) .
Besides the desalkylated metabolites, formation of other minor metabolites by the hydroxylation of the benzene ring at para position (Shin, 1997; Katagi et al., 2002) and by b-hydroxylation (with the formation of ephedrine, pseudoephedrine, norephedrine and norpseudoephedrine) (Shin, 1997) has also been reported in humans. (The scheme of the metabolism is shown in Fig. 3 .) Majority of the parahydroxylated metabolites are excreted in the urine as glucuronide conjugates (Shin, 1997; Szök} o o et al., 2004a) , and such, are regarded as inactive metabolites. In humans, about 10% of the dose was recovered as p-hydroxy-methamphetamine (p-OH-MA) and p-hydroxy-amphetamine (p-OH-A) in the urine. However, in the rats, they were found as the major metabolites of (À)-deprenyl. The total amount of p-hydroxylated compounds; p-OH-A, p-OH-MA and para-hydroxy-desmethyldeprenyl (p-OH-DD) in the urine has reached 50-60% of the dose during 24 h after the last treatment, following a seven-days drug administration, significant proportion (46-64%) of which was excreted as conjugates (Szök} o o et al., 2004a) . Trace amounts of ephedrine-type metabolites were also detected in human urine, although their amount was less than 1% of the dose administered. During b-hydroxylation, the chiral configuration at the a-carbon did not change (Shin, 1997) .
Recently, urinary excretion of another deprenyl metabolite, deprenyl-N-oxide (DNO) has also been demonstrated (Katagi et al., 2001 (Katagi et al., , 2002 . The identification of this metabolite in previous metabolic studies has failed, probably because of the analytical method used. Majority of these studies were performed by gas chromatography after sample derivatization, using acyl reagents (Szebeni et al., 1995; Shin, 1997) , and under the derivatization conditions, DNO can degrade to MA and DD. The higher amount of MA metabolites measured in the studies using GC (Reynolds et al., 1978; Heinonen et al., 1989; Shin, 1997) compared to HPLC=MS method (Katagi et al., 2002) can also be explained by the possible conversion of DNO to MA during sample pre-treatment. The oxidation of the tertiary amine resulting in the formation of N-oxide was suggested to be catalyzed by the flavin-containing monooxygenase (FMO) enzymes (Tsutsumi et al., 2004) . In vitro metabolic studies, using liver microsomal preparations, have shown considerable species-differences in the formation of deprenyl-Noxide (L e evai et al., 2005) . The oxidation of the tertiary amine, the generation of DNO is accompanied by the creation of a new chiral centre on the quaternary nitrogen atom, NS-or NR-deprenyl-N-oxides thus can be formed. Stereoselective DNO formation in rats has been demonstrated in our laboratory with preferred formation of the NS enantiomers; NS-DNO was excreted in 3-5 fold excess in urine compared to the NR-DNO (Tábi et al., 2003) .
Our in vitro metabolism studies using human recombinant FMO enzymes have confirmed that N-oxidation reaction is catalyzed by both FMO1 and FMO3 isoenzymes (Szök} o o et al., 2004b) . When deprenyl enantiomers were incubated with recombinant human FMO1 and FMO3 preparations, respectively, the metabolic conversion showed considerable product stereoselectivity, which was opposite for the two enzyme isoforms. The preferred configuration after oxidation of nitrogen by FMO3 was NR, while it was NS in the FMO1 catalyzed reaction (Table 2 ). More significant product stereoselectivity has been found in case of FMO1. (À)-Deprenyl was more readily oxidized by FMO1, than FMO3. The higher metabolic activity of FMO1, the extrahepatic isoform in humans, toward (À)-deprenyl suggests the importance of extrahepatic organs in the formation of DNO metabolite. Human recombinant FMO1 and FMO3 enzymes have shown not only opposite product stereoselectivity, but their substrate preference was also stereoselective. N-oxidation of (À)-deprenyl is preferred compared to that of S-(þ)-deprenyl. In these studies it was also shown that (À)-MA is a substrate of only the FMO1, but not the FMO3 enzyme. Low amount of (À)-methamphetamine-hydroxylamine was detected in the FMO1 enzymecatalyzed reaction, which was partly further converted to (À)-amphetamine-hydroxylamine. This product is likely reduced to A, in accordance with findings previously reported by Yoshida (Yoshida et al., 1986) . In vivo metabolic studies both in humans and rats indicated the rapid urinary excretion of DNO, mainly in the first 6 hours after (À)-deprenyl dosing (Katagi et al., 2002; Szök} o o et al., 2004a) . Its excreted amount is comparable to that of MA during this period after treatment.
Contribution of the metabolites to the complex pharmacological actions of (À)-deprenyl has been suggested by several authors (Tatton and Chalmers-Redman 1996; Magyar et al., 1998) . Because of their propargyl structure, DNO and DD are the most probable candidates to possess neuroprotective and=or antiapoptotic activity. Pharmacological studies with DNO performed in our laboratory revealed that it possesses antiapoptotic activity similarly to low dose of (À)-deprenyl, without the proapoptotic activity characteristic of high dose of (À)-deprenyl. The impact of the stereoselectivity of DNO formation, and the potential pharmacological differences between the DNO diastereomers require further studies, as well as the elucidation of the role of the N-oxide metabolite in the promising pharmacological effects of (À)-deprenyl.
Neuroprotection by propargylamines: cellular targets in antiapoptotic signalling
Neurodegenerative disorders are characterized by a continuous loss of neurons, that is rather indicative of a slowly progressing apoptotic cell death, than a more drastic and prompt necrotic course. Indeed, apoptosis seems to be more favorable for pharmacologic intervention, because of the broader therapeutic window; necrosis, once begun, is an irreversible process. (À)-Deprenyl was the first propargyl compound that has been shown by Birkmayer's group in a retrospective clinical trial to possess neuroprotective features (Birkmayer et al., 1985; Birkmayer and Birkmayer, 1986) , which was later confirmed by Tatton and his colleagues, who demonstrated that (À)-deprenyl interfered with certain apoptotic events in partially differentiated, serumand NGF-withdrawn PC-12 cells (Tatton et al., 1994) . Since then, the neuroprotective and neuronal rescue activities of (À)-deprenyl and ensuing propargylamines (e.g. rasagiline or N-propargyl-1-aminoindan; TCH346, also known as CGP 3466B; 2-HMP or 2-heptyl-N-methylpropargylamine) have been justified in a huge variety of in vitro and in vivo models (for an overview, see Tabakman et al., 2003; Waldmeier and Tatton, 2004) ; however, their exact mechanism of action still challenges today's scientists. The antiapoptotic activity of (À)-deprenyl and other related propargylamines (DRPs) is centered upon the protection of mitochondria (Wadia et al., 1998; Naoi et al., 2002) . Dissipation of the mitochondrial transmembrane potential (ÁÉ m ) initiates an apoptotic cascade by opening of the mitochondrial membrane permeability transition pore (PTP), a complex channel through which several proapoptotic factors (e.g. cytochrome-c, apoptosis inducing factor, Smac= DIABLO, etc.) leak to the cytoplasm. In the cytoplasm they assemble into an apoptosome that is able to activate effector caspases, responsible for the execution of the apoptotic program. The role of Bcl-2 protein members in controlling PTP is also of major interest, and their regulation by propargylamines has also been confirmed (Tatton et al., 2002; Mandel et al., 2005) . The Bcl-2 protein family is composed of death inhibitors (Bcl-2, Bcl-X L , Bcl-w), as well as death promoters (Bcl-X S , Bad, Bax, Bak, Bid), the actual ratio of which is decisive from the point of view of cell survival or death. Bcl-2 proteins can translocate to the mitochondrial membrane, where they enhance or inhibit the increase in membrane permeability (Jayanti et al., 2001 ). (À)-Deprenyl and rasagiline have been demonstrated to elevate the levels of Bcl-2 and Bcl-X L and decrease that of Bax and Bad to maintain ÁÉ m and mitochondrial integrity. Mitochondria are a major focus, on which a number of proapoptotic events converge, still, it is not fully understood, whether propargylamines directly influence PTP through binding to MAO-B or a similar structure, located in the mitochondrial membrane, or interfere exclusively with upstream events, thus halting the process before it comes to mitochondria. Surely, both assumptions have a rationale and do not exclude each other. Besides the Bcl-2 proteins, propargylamines upregulate members of antioxidant enzyme systems (e.g. SOD, catalase, heat shock protein 70), while downregulating those of some signal transduction routes favoring apoptosis (c-Jun, c-Fos, glyceraldehyde-3-phosphate dehydrogenase; GAPDH) (Tatton et al., 2002; Mandel et al., 2005) .
Propargylamines, originally developed as MAO-B inhibitors, exert their antiapoptotic effect at the transcriptional level, most probably independently of their enzyme inhibitory action, by modulating the expression of a number of genes resulting in new protein synthesis (Tatton et al., 1996; Maruyama et al., 2002) . The propargyl moiety seems to be essential for the neuroprotective action. N-propargylamine itself proved to be enough to stabilize mitochondrial membrane potential and protect SH-SY5Y cells and partially NGF-differentiated PC12 cells in vitro, though this effect was relatively weak (Yi et al., 2006; Weinreb et al., 2004) , while substances lacking the propargyl group failed to prevent apoptosis (e.g. aminoindan, (R)-3-(2-heptylamino)-propionic acid) . Proper stereochemical configuration of the propargylamine residue is of equal importance, since R-enantiomers of deprenyl, rasagiline and 2-HMP proved to be more potent antiapoptotic agents than the S-enantiomers that may even be free of this beneficial activity Magyar et al., 1996; Szende et al., 2001) .
The establishment of structure-activity relationships can be useful to find the active metabolites of propargylamines that may undergo extensive metabolism in the organism. Rasagiline is metabolised to aminoindan that lacks the propargyl moiety, thus, rasagiline itself conveys the antiapoptotic features. In case of (À)-deprenyl, metabolic inhibition was able to eliminate the antiapoptotic character in cell culture, so an active metabolite was proposed to be responsible for preventing cell death (Magyar and Szende, 2000; Szende et al., 2001; Tatton et al., 2002) . Deprenyl is metabolized mostly to (À)-DD, (À)-DNO and (À)-MA in vivo; the first two are suitable candidates of blocking apoptosis, whereas the third one is supposed to diminish this potency by its neurotoxic character. (À)-MA has been shown to interfere with the neuroprotective activity of (À)-deprenyl in a concentration equal to the parent compound , 2002) . Though the evidence available does not prove unequivocally that the neurotoxic features of (À)-MA negatively influence the antiapoptotic activity of (À)-deprenyl, rasagiline has been synthesized, the metabolite of which, aminoindan, is supposed to be free of neurotoxic effects . Propargylamines influence certain signal transduction pathways within the cell. Rasagiline upregulates the phosphorylated a and e isoforms of protein kinase C (PKC), which are involved in the non-amyloidogenic a-secretase pathway of amyloid precursor protein (APP) processing, an advantageous feature in treating Alzheimer's disease. The propargylamine moiety is a prerequisite for this activity too, and (À)-deprenyl, as well as N-propargylamine also bear this capacity (Yogev-Falach et al., 2003) . A downstream event of PKC activation is phosphorylation of MARCKS (myristoilated alanine-rich C-kinase substrate) and upregulation of RACK-1 (receptor for activated C kinase 1), the deficit of which may contribute to Alzheimer's disease and ageing. Rasagiline enhances the phosphorylation and translocation of PKCa and e to the hippocampal membrane compartment. Phosphorylated PKC activates the MAP kinase (MAPK)=extracellular signal-regulated kinase (Erk) cascade, a known inhibitor of apoptosis, and the a-isoform induces the overexpression of Bcl-2 (Mandel et al., 2005) .
Recently, (À)-deprenyl has been shown to protect human SH-SY5Y neuroblastoma cells and mouse primary dopaminergic neurons against MPP þ -toxicity through the upregulation of the redox-active protein, thioredoxin (Andoh et al., 2005) . Thioredoxin enhances the DNA binding of some transcription factors (NF-kB, AP-1) and induces Bcl-2 and MnSOD in response to oxidative stress, which promotes cell survival. The mechanism by which (À)-deprenyl upregulates thiredoxin levels is yet unclear, but it may be accomplished via the induction of redox-responsive c-Myc or c-Jun. These transcription factors are activated by protein kinase A mediated phosphorylation of MAPK=Erk1=2, which is translocated to the nucleus to induce c-Myc; or directly through phosphorylation of c-Myc by protein kinase G.
(À)-Deprenyl is antiapoptotic in a dose that is far too low to block MAO-B, thus MAO-B inhibitory action is considered to convey no benefit from the point of view of antiapoptosis. Still, binding to MAO-B or other related NAD-or FAD-containing enzymes, with or without an alteration in enzyme activity, cannot be ruled out as a possible mechanism of action. Recently, a direct link has been established between transcriptional regulation and the metabolic state of the cell, which necessitates the re-evaluation of the role of metabolic enzymes and their cofactors in gene transcription (Shi and Shi, 2004) . These metabolism-related transcription factors are homologues of known metabolic enzymes that retain either their enzymatic activity or the ability to bind metabolic cofactors without being enzymatically active. Besides the intrinsic enzymatic activity, cofactors may be required for proper DNA-binding or for stabilizing protein-protein interactions in the final transcription factor complexes. NAD and FAD are the most common representatives of these, often redox-active, cofactors that map and convert changes in the cellular redox state to a complex transcriptional response.
DRPs are most likely inserted into the FAD-pocket of MAO-B, with pargyline shown to be covalently bound to N 5 of the flavin nucleotide (Binda et al., 2002) . Propargylamines also bind GAPDH, the NAD-binding site of which is structurally similar to other FAD-containing enzymes, e.g. MAO-B. Therefore, it may not be a far too weird idea to suppose, that DRPs may target other enzymes as well using FAD or NAD as their cofactor. So far, three classical metabolic enzymes have been investigated as a possible target of DRPs (MAO-B, GAPDH and poly(ADP-ribose)-polymerase-1; PARP-1), that function with the above mentioned cofactors. The success in future research may lie in delineating the role of propargylamines as modifiers of transcriptional activity of these enzymes or their related homologues. DRPs have been demonstrated to bind glyceraldehyde-3-phosphate dehydrogenase (GAPDH), the well known glycolytic enzyme. Besides having central roles in energy metabolism, GAPDH participates in a nuclear apoptotic pathway, via overexpression, aggregate formation and translocation to the nucleus in tetrameric form (Sawa et al., 1997; Ishitani et al., 1998) . One of the upstream regulators of GAPDH expression is p53, a critical regulator of cell cycle and apoptosis, which mediates translocation and nuclear accumulation (Chen et al., 1999) . Apoptotic cell death may contribute to the progression of neurodegenerative diseases, and GAPDH has been shown to co-immunoprecipitate with the mutant, denaturated proteins accumulating in the nucleus in PD, Alzheimer's (AD), Huntington's and some triplet repeat genetic disorders (Mazzola and Sirover, 2002) . Their role in disease progression is still unclear, and we do not know how GAPDH contributes to this process either. Knockdown of GAPDH by antisense oligonucleotides prevents its nuclear translocation and initiation of the apoptotic machinery, thus translocation of the mutant proteins together with GAPDH seems to be more decisive in cell death than nuclear aggregate formation (Fukuhara et al., 2001) . GAPDH may function as a molecular carrier or chaperone, stabilizing a given conformation of the mutant proteins in order to be translocated to the nucleus and initiate neuronal apoptosis. Whether these new functions of GAPDH are in connection with energy status or an altered glycolytic capacity is yet to be elucidated.
For all the above mentioned, GAPDH seems to be a suitable target for influencing neurodegenerative processes. Although the precise role of GAPDH in neuronal apoptosis remains to be clarified, this is the first selective target reported in connection with DRPs concerning antiapoptotic action (Kragten et al., 1998; Carlile et al., 2000) . GAPDH binds NAD þ at a site structurally similar to that of the FAD-binding enzymes, and DRP binding site is near the NAD-binding site. DRPs can prevent the overexpression, aggregate formation and nuclear translocation of GAPDH by converting the enzyme to a dimeric state that is less prone to translocation with retained or increased glycolytic capacity (Minton and Wilf, 1981) . Glycolytic activity of cells undergoing apoptosis has been shown to be increased, possibly due to overexpression of tetrameric GAPDH, whereas (À)-deprenyl treatment caused a relative decrease in glycolysis, which is the net effect of the elevated glycolytic capacity of the dimer and the prevention of the increase in GAPDH levels (Carlile et al., 2000) . Whether altered energy status, or neuron-specific transcriptional control, or some other functions of GAPDH is of primary importance in connection with apoptosis, requires further elucidation. PARP is a nuclear enzyme that hydrolizes NAD þ to poly(ADP-ribosyl)ate a number of nuclear targets after DNA damage. Besides, but certainly in connection with, its inevitable role in DNA repair, PARP also regulates transcription either by modifiying chromatin structure or directly participating in enhancer=promoter binding complexes (for review, see Kraus and Lis, 2003; Meyer-Ficca et al., 2005) . Histones H1 and H2B are readily ADP-ribosylated by PARP, which induces chromatin decondensation resulting in further exposure of DNA. This phenomenon may be observed in cells not subject to DNA damage as well. Though shorter polymers are generated, it may still be sufficient to induce transcriptional changes. PARP has also been shown to poly(ADP-ribosyl)ate a number of transcription factors in vitro (YinYang1, NF-kB, etc.) preventing their DNA-binding. However, PARP may also function as a transcriptional co-activator directly interacting with non-histone proteins e.g. NF-kB, B-Myb, Oct-1, and facilitating the formation of enhancosome-like complexes. In this respect, co-repression also seems feasible. Enzymatic activity may not be a prerequisite for the functional interaction with transcription factors. PARP is considered as the guardian of the genom that maintains its stability through enabling DNA repair (Bouchard et al., 2003) . On the other hand, PARP ''sentences the cell to death'' by overactivation and subsequent depletion of NAD and ATP stores resulting in a failure of energy metabolism and necrosis, when DNA damage is so excessive, that repair enzymes cannot cope with. A transient activity burst of PARP is also dispensible for the initiation of the apoptotic process, but cleavage of the enzyme by caspase 3 and 7, and a consequent loss of activity is required for the appropriate execution of apoptosis. Hitherto, only one report exists that deals with the interaction of (À)-deprenyl with PARP-1. Recently, (À)-deprenyl has been reported to potentiate the cellular poly(ADPribosyl)ation in response to ionizing g-radiation (Brabeck et al., 2003) . A 40-fold increase in poly(ADP-ribose) (PAR) levels could be observed in control irradiated COR4 cells compared to control unirradiated. After (À)-deprenyl pretreatment ranging from 8 h to 7 days an up to 1.8-fold increase was reported in PAR levels, shorter duration of pretreatment did not lead to statistically significant effects. 3 days of (À)-deprenyl treatment without irradiation did not alter PAR levels; however, downregulated PARP-1 protein levels by 40% compared to control. (À)-Deprenyl did not potentiate DNA strand breakage of g-irradiated cells, and did not influence significantly the activity of human recombinant PARP-1 in vitro in a concentration range of 50 nM-5 mM. Poly(ADP-ribosyl)ating capacity has been demonstrated to correlate with the longevity of different species and (À)-deprenyl, accordingly, increased the lifespan of some laboratory animals , that may be attributed to the enhancement of the poly(ADPribosylation) response to genotoxic stress. Despite of the controversies, the influence of (À)-deprenyl on PARP-1, another NAD-binding enzyme, seems quite conceivable, and offers a brand new field of research from the point of view of transcriptional regulation in connection with neuroprotective potential.
Maintaining genomic stability would further extend (À)-deprenyl's pharmacological profile from neuroprotection to a more general cytoprotective effect. Indeed, (À)-deprenyl and clorgyline (an irreversible inhibitor of MAO-A) have been shown to protect non-tumorigenic cell lines (HaCaT, immortal human keratinocyte) and explant cultures (normal uroepithelium) after g-irradiation or cisplatin treatment by enhancing Bcl-2 expression (Seymour et al., 2003) . Tumorigenic cell lines (HaCaT-ras, HPV-G; tumorigenic human keratinocyte, PC3; human prostate adenocarcinoma) and bladder tumor explants showed no protection; moreover, (À)-deprenyl potentiated delayed reproductive death in case of tumorigenic cell lines. However, Bcl-2 overexpression cannot be the sole reason for the protective effect of MAO inhibitors, but other contributors in this sense are unknown to date. (À)-Deprenyl may also be a potent inhibitor of non-neuronal apoptosis in case of the cardiac and renal tissue (Qin et al., 2003; Toronyi et al., 2002) , further demonstrating that the protective effect of (À)-deprenyl cannot be confined to neurons or neuron-like cells.
Adequate trophic support may protect or rescue dying neurons in several in vitro and in vivo models. (À)-Deprenyl upregulates the mRNA and protein levels of FGF2, NGF, BDNF and GDNF in cultured astrocytes of different species (Semkova et al., 1996; Riva et al., 1997; Mizuta et al., 2000) . The mechanism of action, by which (À)-deprenyl alters neurotrophin levels, is not clear, but the activation of astrocytes and the consequent secretion of various cytokines and neurotrophic factors may contribute to the neuroprotective capacity (Biagini et al., 1994) . However, it should be kept in mind, that excessive activation of glial cells may exacerbate cell damage through increased production of reactive oxygen species and augmenting the inflammatory response. Rasagiline has also been shown to increase the transcription of GDNF in human neuroblastoma Fig. 4 . Possible targets of (À)-deprenyl and related propargylamines in antiapoptotic signalling. DRPs prevent apoptosis by maintaining mitochondrial transmembrane potential through elevated expression of Bcl-2 and decreased expression of Bax. The role of MAO-B, located in the outer mitochondrial membrane, in this process and their blockade by DRPs is still elusive. DRPs convert tetrameric GAPDH to a dimer, thus preventing its overexpression and nuclear translocation that would otherwise initiate an apoptotic program. DRPs also influence protein kinase cascades which further contributes to the neuroprotective potential. Finally, (À)-deprenyl enhances the poly(ADP-ribosyl)ation response to genotoxic stress, promoting repair mechanisms and cell survival. Influencing NAD or FAD binding transcription factor complexes is a hitherto unexplored field in DRP research, which may have a rationale in future. Abbreviations: AIF: apoptosis inducing factor, ber: base excision repair, Cyt c: cytochrome c, DEP: (À)-deprenyl, DRPs: deprenyl related propargylamines, GAPDH: glyceraldehyde-3-phosphate dehydrogenase, IAP: inhibitor of apoptosis, MAO-B: monoamine oxidase B, NAD=FAD TFC: NAD=FAD binding transcription factor complexes, oe: overexpression, PARP: poly(ADP-ribose) polymerase, PTP: permeability transition pore, ÁÉ m : mitochondrial transmembrane potential Deprenyl: from chemical synthesis to neuroprotection cell line through an NF-kB-mediated pathway enhancing the phosphorylation of IkB (Maruyama et al., 2004) . NF-kB is a two-edged sword in cell death, promoting the transcription of cell survival genes or activating proapoptotic factors depending on the type of cell and conditions of cytotoxic stimuli.
Today, propargylamines presumably interfere with apoptosis, and exert neuroprotective and neurorescue activities by targeting a wide variety of cellular components and influencing multiple pathways of cell death (Fig. 4) . The relevance of each of these targets as well as the interdependence of the various routes affected by propargylamines from the point of view of cell survival will be established by future research. Nevertheless, the complex transcriptional changes underlying the effect of these drugs necessitates to reconsider the role of their classical metabolic targets (GAPDH, MAO, PARP) paying more attention to their possible influence of gene expression.
The effect of ( 2 )-deprenyl on cellular functions and signalling
The neuroprotective effect of (À)-deprenyl has been explained by a number of independent theories, including effects on cellular signalling pathways, such as pro-and antiapoptotic pathways, redox signalling or trophic effects of the drug. The pro-and antiapopotic actions of (À)-deprenyl has been described in the previous chapter.
Recently, our research group described a novel, MAO-B independent effect of (À)-deprenyl on cell-cell adhesion, which can also contribute to the protective effect of the drug. We showed that (À)-deprenyl increases cell-cell adhesion of NGF-na€ ve and NGF-differentiated PC12 cells (originated neuro-ectodermally) and NIH3T3 fibroblasts (non-neuronal) in a concentration-dependent manner (Jenei et al., 2005) . Previous results have also shown that (À)-deprenyl is not only neuroprotective, but also protects cells of non-neuronal origin. (À)-Deprenyl can diminish the apoptosis-inducing effect of ischemia-reperfusion in rat kidney (Toronyi et al., 2002) , protects the vascular endothelium from the toxic effects of amyloid-beta peptide (Thomas et al., 1998) and reduces myocyte apoptosis in vivo (Qin et al., 2003) .
We cannot exclude that the cell-cell adhesion-increasing effect of (À)-deprenyl can, to some extent, be attributed to its antiapoptotic effect. Nevertheless, comparison of the antiapoptotic and cell-cell adhesion increasing properties of the drug revealed, that the two functions are most probably, not based on the same mechanism. While both the antiapoptotic and cell-cell adhesion increasing effect of (À)-deprenyl are MAO-B independent, and the (þ)-enantiomer of deprenyl was not effective either against apoptosis or in induction of cell-cell adhesion Tatton et al., 1994; Jenei et al., 2005) , some differences were also found between the two actions of the drug. In case of NIH3T3 cells, the drug was effective in induction of cell-cell adhesion in very low concentrations (10 À11 -10 À12 M), however, in PC12 cells the effective concentration range was higher (10 À7 M in NGF-na€ ve and 10 À9 M in NGF-differentiated PC12 cells) than the antiapoptotic concentrations (10 À11 M in PC12, 10 À13 M in melanoma) (Tatton et al., 2002; Szende et al., 2001 ). According to Tatton and his co-workers, (À)-deprenyl prevents apoptotis only of NGF-differentiated PC12 cells, while in our experiments (À)-deprenyl induced cell-cell adhesion of NGF-na€ ve PC12 cells too, which is another important difference. In several cases, it has been reported that the metabolites of (À)-deprenyl are responsible for the antiapoptotic effects of the drug (Tatton et al., 1996; Szende et al., 2001 ). In our experiments, SKF525A, an unspecific inhibitor of microsomal drug metabolism, failed to prevent the cell-cell adhesion-inducing effect of (À)-deprenyl, which suggests that this novel action of the drug does not require cytochrome P450-dependent metabolism of (À)-deprenyl. N-oxidation of (À)-deprenyl by flavin containing monooxygenase (FMO) enzymes has also been described (Katagi et al., 2001) . Although DNO in a concentration of 10 À5 M significantly induced cell-cell adhesion of NGF-na€ ve PC12 cells, this metabolic pathway does not seem to be essential for the effect either, since methimazole (an inhibitor of FMO enzymes) does not appeared to block the effect of (À)-deprenyl on cell-cell adhesion (V. Jenei unpublished results). The role of cell adhesion has been implicated in a number of processes, which can be involved in the pathogenesis of PD and AD. Cell-matrix and cell-cell adhesion can have regulatory function in cell proliferation and survival by activating signalling cascades via integrins and cadherins. This way, adhesion can affect the survival of neurons in neurodegenerative disorders. Although the central nervous system has been considered for a long time to be unable to generate new neurons, by now, a growing number of studies have showed neuroregeneration in certain areas of the adult mammalian brain including the subgranular zone (SGZ) of the hippocampus, or the subvenricular zone (SVZ) of the lateral ventricles. Recent evidences have shown increased neurogenesis in the hippocampus in AD (Jin et al., 2004) . Another recent study showed that precursor cell proliferation in the subependymal zone is impaired in PD due to the loss of DA (Höglinger et al., 2004) . The existence and importance of neurogenesis in the adult mammalian substantia nigra is not yet clear. It has been shown that progenitor cells exist and can proliferate in this brain region, and some studies have suggested that neurogenesis also occurs in the substantia nigra (Yoshimi et al., 2005; Zhao et al., 2003) . Although these findings are still controversial and not all studies could confirm the existence of dopaminergic neurogenesis in this brain region (Frielingsdorf et al., 2004) , it cannot be excluded that impaired or insufficient neurogenesis can also contribute to the progression of PD and AD. Cell-cell adhesion is an important process during differentiation and this way neurogenesis as well (Schlett et al., 2000; Hamada-Kanazawa et al., 2004; Laplante et al., 2004) , therefore, it is possible that (À)-deprenyl can affect neurogenesis by inducing cell-cell adhesion. Formation of cell-cell contacts is an essential step in synaptogenesis and structural plasticity (the reorganization of synaptic connections) (Garner et al., 2002) , which are targets for protective treatments to slow down AD progression and preserve cognitive and functional abilities. Therefore, the positive effect of (À)-deprenyl on cell-cell adhesion could also provide an explanation of the effect of the drug on cognitive functions in AD, which have been shown in some clinical trials (Falsaperla et al., 1990) .
It is important to mention here that (À)-deprenyl has been shown to increase the expression of several neurotrophic factors (NGF, BDNF, GDNF, FGF2, IGF1) primarily in astrocytes, which also has the potential to induce survival signals and cell proliferation of progenitor cells in PD and AD (Mizuta et al., 2000; Riva et al., 1997; De la Cruz et al., 1997) .
Conclusions
For three decades (À)-deprenyl has been widely used to treat Parkinson's disease, as a consequence of its dopaminepotentiating and antioxidant activity related to MAO-B inhibition. The parent compound itself is primarily responsible for these effects, but the metabolites might also contribute to the complex pharmacological activity of the drug. Usually (À)-deprenyl is administered orally in human therapy, thus, special attention should be paid to the intensive first pass metabolism of the drug (75% of the dose). Increasing the concentration of the parent compound that reaches the systemic circulation might be beneficial; this can be achieved by choosing a more adequate route of administration (nasal spray, transdermal patches). Nevertheless, it has never been noticed, that the (À)-isomers of amphetamin-like metabolites, formed from (À)-deprenyl during metabolism, induce significant amphetaminergic pharmacological activities in doses required for selective MAO-B inhibiton.
Currently, special attention is focused on the effects of (À)-deprenyl in tissue cultures, in concentrations too low to induce MAO-B inhibition. Many laboratories, including ours, investigated the effects of (À)-deprenyl in nanomolar or even lower concentrations in vitro and demonstrated that the drug possesses antiapoptotic activity. We have published in 2005 that (À)-deprenyl increases cell adhesion as well. The presence of the propargylamine moiety in the molecule seems indispensable to induce these effects. A good deal of knowledge has accumulated in this field, indicating that an altered complex transcriptional program may be responsible for these activities. In vitro studies clearly demonstrate that (À)-deprenyl has a bell-shaped dose-response curve in respect of neuroprotection, which ought to be taken more intensely into consideration during the therapeutic usage of the drug. Finally, it may be concluded that the results obtained in preclinical studies should be considered in human therapy as well, because it could possibly broaden the therapeutic applicability of (À)-deprenyl.
